Value and significance of brain radiation therapy during first‐line EGFR‐TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique-Reference-Cited by-同舟云学术

Value and significance of brain radiation therapy during first‐line EGFR‐TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique

Published:2021-10-14 Issue:23 Volume:12 Page:3157-3168
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Gu Yangchun¹^ORCID,Xu Yan²^ORCID,Zhuang Hongqing³,Jiang Weijuan³,Zhang Hua⁴,Li Xiaofeng⁵,Liu Yonggang⁵,Ma Li⁶,Zhao Dahai⁷^ORCID,Cheng Yuan⁸^ORCID,Yu Yan⁹^ORCID,Liu Ping¹⁰,Qin Jianwen¹¹,Chen Xueqin¹²,Gao Junzhen¹³,Wang Mengzhao²,Liang Li¹,Cao Baoshan¹

Affiliation:

1. Department of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing China

2. Department of Respiratory and Critical Care Medicine Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China

3. Department of Radiation Oncology Peking University Third Hospital Beijing China

4. Research Center of Clinical Epidemiology Peking University Third Hospital Beijing China

5. Internal Medicine of Thoracic Oncology, Baotou Tumor Hospital Baotou China

6. Department of Medical Oncology Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute Beijing China

7. Department of Respiratory and Critical Care Medicine The Second Affiliated Hospital, Anhui Medical University Hefei China

8. Department of Respiratory and Critical Care Medicine Peking University First Hospital Beijing China

9. Department of respiratory medicine Harbin Medical Cancer Hospital Harbin China

10. Department of Respiratory and Critical Care Medicine the First Hospital of Changsha Changsha China

11. Department of Respiratory and Critical Medicine Tianjin Chest Hospital Tianjin China

12. Department of Thoracic Oncology Hangzhou cancer Hospital, Zhejiang University School of Medicine Hangzhou China

13. Department of Respiratory and Critical Care Medicine The Affiliated Hospital of Inner Mongolia Medical University Hohhot China

Funder

Peking University Third Hospital

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14169

Reference33 articles.

1. Challenges and Novel Opportunities of Radiation Therapy for Brain Metastases in Non-Small Cell Lung Cancer

2. Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma

3. Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer

4. A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

5. EGFR mutant locally advanced non-small cell lung cancer is at increased risk of brain metastasis

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MRI radiomics predicts the efficacy of EGFR-TKI in EGFR-mutant non-small-cell lung cancer with brain metastasis;Clinical Radiology;2024-07

2. First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis;BMC Cancer;2023-10-30

3. Effect of Different Timing of Local Brain Radiotherapy on Survival of EGFR-Mutated NSCLC Patients with Limited Brain Metastases;Brain Sciences;2023-09-03

4. Preoperative MRI ‐Based Radiomics of Brain Metastasis to Assess T790M Resistance Mutation After EGFR‐TKI Treatment in NSCLC;Journal of Magnetic Resonance Imaging;2022-09-27

5. Prognostic Factors and Survival Benefits of Antitumor Treatments for Advanced Non-Small Cell Lung Cancer Patients With Central Nervous System Metastasis With or Without Driver Genes: A Chinese Single-Center Cohort Study;Frontiers in Oncology;2022-04-26